The failure to achieve and maintain remission is a critical problem for a high percentage of patients with epilepsy and the primary affective disorders. Early illness onset and delayed initiation of treatment may contribute to primary treatment resistance or that associated with loss of efficacy (tolerance phenomenon).
Neurobiological data and principles drawn from the amygdala kindling model of seizure progression are reviewed for their heuristic value in conceptualizing molecular mechanisms of illness progression and its prevention with pharmacological agents in the epilepsies and, indirectly, the recurrent affective disorders. Caveats in the use of this model and convergences and divergences in its predictive validity for seizures and affective disorders are noted.
KwanPBrodieMJ. Refractory epilepsy: A progressive, intractable but preventable condition?Seizure2002;11:77–84.
2.
MajMPirozziRMaglianoLBartoliL.Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry1998;155:30–35.
3.
DenicoffKDSmith-JacksonEEDisneyERAliSOLeverichGSPostRM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry1997;58:470–478.
4.
GoldbergJFHarrowMLeonAC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull1996;32:47–54.
5.
GumnickJFNemeroffCB. Problems with currently available antidepressants. J Clin Psychiatry2000;61(suppl)10:5–15.
6.
KraepelinE.Manic-depressive insanity and paranoia. Edinburgh: E.S. Livingstone; 1921.
7.
KessingLVAndersenPKMortensenPBBolwigTG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry1998;172: 23–28.
8.
PostRM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry1992;149:999–1010.
9.
KendlerKSThorntonLMGardnerCO. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the “kindling” hypothesis. Am J Psychiatry2000;157:1243–1251.
10.
KendlerKSThorntonLMGardnerCO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry2001;158:582–586.
11.
GoddardGVMcLntyreDCLeechCK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol1969;25:295–330.
12.
RacineR.Kindling: The first decade. Neurosurgery1978;3:234–252.
13.
WeissSRPostRM. Caveats in the use of the kindling model of affective disorders. Toxicol Ind Health1994;10:421–447.
14.
ReynoldsEH. Early treatment and prognosis of epilepsy. Epilepsia1987;28:97–106.
15.
PostRMDenicoffKDLeverichGSAltshulerLLFryeMASuppesTM. Presentations of depression in bipolar illness. Clin Neurosci Res2002;2:142–157.
16.
WeissSRClarkMRosenJBSmithMAPostRM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Res Rev1995;20:305–325.
17.
PazzagliaPJPostRM. Contingent tolerance and reresponse to carbamazepine: A case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci1992;4:76–81.
18.
PostRMLeverichGSRosoffASAltshulerLL. Carbamazepine prophylaxis in refractory affective disorders: A focus on long-term follow-up. J Clin Psychopharmacol1990;10:318–327.
19.
KruppEHeynenTLiXLPostRMWeissSR. Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: Cross-tolerance to carbamazepine but not valproate or diazepam. Exp Neurol2000;162:278–289.
20.
WeissSRPostRMSohnEBergerALewisR.Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Res1993;16:37–44.
21.
ClarkMMassenburgGSWeissSRPostRM. Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. Brain Res Mol Brain Res1994;26:309–319.
22.
ZhangZJRussellSObengKPostmaTObroceaGWeissSRPostRM. Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacol Biochem Behav2003;74:565–571.
23.
PostRMWeissSR. Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: Therapeutic versus pathogenic. Biol Psychiatry1992;32: 469–484.
24.
WanRQNogueraECWeissSR. Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuro Report.1998;9: 677–682.
25.
PinelJPJ. Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: A double dissociation. Pharmacol Biochem Behav1983;18:61–63.
26.
IudiceAMurriL.Pharmacological prophylaxis of post-traumatic epilepsy. Drugs2000;59:1091–1099.
27.
AltshulerLLPostRMLeverichGSMikalauskasKRosoffAAckermanL.Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry1995;152:1130–1138.
28.
ObroceaGVDunnRMFryeMAKetterTALuckenbaughDALeverichGS. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry2002;51:253–260.
29.
PazzagliaPJPostRMKetterTAGeorgeMSMarangellLB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res1993;49:257–272.
30.
PazzagliaPJPostRMKetterTACallahanAMMarangellLBFryeMA. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol1998;18:404–413.
31.
KramlingerKGPostRM. Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry1996;168:314–323.
32.
DumanRS. Synaptic plasticity and mood disorders. Mol Psychiatry2002;7(suppl1): S29–S34.
33.
NibuyaMMorinobuSDumanRS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci1995;15:7539–7547.
34.
WhiteHS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia1999;40(suppl5):S2–S10.
35.
PostRMBerrettiniWHUhdeTWKellnerCH. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: A case study. J Clin Psychopharmacol1984;4:178–185.
36.
PostRMAltshulerLLKetterTADenicoffKWeissSRB. Antiepileptic drugs in affective illness: Clinical and theoretical implications. In: SmithDBTreimanDMTrimbleMR, (eds). Advances in Neurology: Neurobehavioral Problems in Epilepsy. New York: Raven Press; 1991;55: 239–277.
37.
ManjiHKLenoxRH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry1999;46: 1328–1351.
38.
BebchukJMArfkenCLDolan-ManjiSMurphyJHasanatKManjiHK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry2000;57:95–97.
39.
PassmoreMJGarnhamJDuffyAMacDougallMMunroASlaneyC. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar disord2003;5:110–114.
40.
PostRMSpeerAMWeissSRLiH.Seizure models: Anticonvulsant effects of ECT and rTMS. Prog Neuropsychopharmacol Biol Psychiatry2000;24:1251–1273.
41.
GeorgeMSSackeimHARushAJMarangellLBNahasZHusainMM. Vagus nerve stimulation: A new tool for brain research and therapy. Biol Psychiatry2000;47:287–295.
42.
RushAJGeorgeMSSackeimHAMarangellLBHusainMMGillerC. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry2000;47:276–286.
43.
MarangellLBRushAJGeorgeMSSackeimHAJohnsonCRHusainMM. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry2002;51:280–287.
44.
SackeimHARushAJGeorgeMSMarangellLBHusainMMNahasZ. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome. Neuropsychopharmacology2001;25:713–728.
